Möchten Sie immer auf dem neuesten Stand bleiben?

Clinical activity observed in 50% of evaluable patients with relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) treated with RVU120 monotherapy,...

Translational data demonstrate synergistic activity of RVU120 and MEK inhibitors in hormone receptor-negative breast cancer KRAKOW, Poland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics...

The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022.Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of...

KRAKOW, Poland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

Poster presentations highlight preclinical data from Ryvu’s PRMT5 program in MTAP-Deficient cancers and its synthetic lethality platform in colorectal cancer modelsVirtual webinar on PRMT5 data and...

The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022.Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA)...

Ongoing Phase 1b Dose-Escalation Study of Single-Agent Treatment with RVU120 in Patients with AML or High-Risk MDS Shows Clinical Benefit and Favorable Safety;Dose-Escalation Continues, Currently...

Updated Clinical Data from the Ongoing Phase Ib Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS and Preclinical Data from the Combination Study of RVU120 and Ruxolitinib in...

Updated Clinical Data from the Ongoing Phase 1b Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS Show Favorable Safety and Promising Signs of EfficacyPoster Presentation to...

Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment, €20M equity investment in Ryvu,...